Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda

AIDS

Volumn 21, Issue 8, 2007, Pages 965-971

  Oyugi, Jessica H ^a   Byakika Tusiime, Jayne ^b   Ragland, Kathleen ^d   Laeyendecker, Oliver ^e   Mugerwa, Roy ^b   Kityo, Cissy ^c   Mugyenyi, Peter ^c   Quinn, Thomas C ^e   Bangsberg, David R ^d,f  

^a Infectious Diseases Institute   (Uganda)

^b MAKERERE UNIVERSITY   (Uganda)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d Division of Infectious Diseases   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Africa; Antiretroviral treatment; Finances; Fixed dose combination; Generic; HIV AIDS; Resistance; Treatment interruptions

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ADHESION; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FINANCING, PERSONAL; GENOTYPE; HEALTH CARE RATIONING; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PSYCHOMETRICS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UGANDA; VIRAL LOAD;

EID: 34247571878     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32802e6bfa     Document Type: Article

References (32)

1. UNAIDS. Report of the global AIDS epidemic. Geneva: UNAIDS; 2006.
2. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
3. Lule F. Monitoring and evaluation, AIDS control program. Kampala, Uganda: Ministry of Health; 2006.
4. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, Bangsberg DR. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36:1100-1102.
5. Beck A, Ward C, Mendelson M. An inventory for measuring depression. Arch Psychiatry 1961; 4:561-567.
6. Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology 1998; 31:160-168.
7. Saunders J, Aasland O, Babor T, de la Fuente J, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption - II. Addiction 1993; 88:791-804.
8. Justice AC, Holmes W, Gifford AL, Rabeneck L, Zachin R, Sinclair G, et al., for the Adults AIDS Clinical Trials Unit Outomes Committee. Development and validation of a selfcompleted HIV symptom index. J Clin Epidemiol 2001; 54 (Suppl. 1):S77-S90.
9. Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R. HIV reverse transcriptase and sequence database. Nucl Acids Res 2003; 31:298-293.
10. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to antiretroviral therapy in HIVinfected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42:252-259.
11. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eshleman SH. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 2000; 16:807-813.
12. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17.
13. Mills EJ, Nachega JB, Buchan I, Orbinski J, Altaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690.
14. Orrell C, Bangsberg D, Badri M, Wood R. Adherence is not a barrier to delivery of HIV antiretroviral therapy in resource-poor countries. AIDS 2003; 17:1369-1375.
15. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34.
16. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002; 17:812-813.
17. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
18. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of selfreport and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423.
19. Liu H, Golin CE, Miller LG, Hays RD, Beck K, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977.
20. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIVR Ugandan patients purchasing therapy. Int J STD AIDS 2005; 16:38-41.
21. Crane JT, Kawuma A, Oyugi JH, Byakika JT, Moss A, Bourgois P, Bangsberg DR. The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 2006; 10:437-442.
22. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3:e438.
23. Bangsberg DR, Ware N, Simoni J. Adherence without access to antiretroviral therapy in sub-Saharan Africa. AIDS 2005; 20:140-141.
24. Parienti J, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, Verdon R. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenzbased antiretroviral therapy. Clin Infect Dis 2004; 38:1311-1316.
25. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunk WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in population of African and Asian origin: allele frequencies, novel functional variants, and possible implication for anti-HIV therapy with efavirenz. Pharmacogenet Genom 2005; 15:861-872.
26. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-407.
27. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192:1931-1942.
28. Van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464-470.
29. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-163.
30. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
31. Oyugi J, Angemi D. Welfare assessment of Ugandans selfpaying for generic antiretroviral therapy. In: XVth International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 [Abstract ThPeE7936].
32. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention? HIV Clin Trials 2002; 3:45-51.